Abbreviations: NOACs: Novel oral anticoagulants; AF: Atrial fibrillation; COMBINE AF: A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation; ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AVERROES: Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; VTE: Venous thromboembolism; ACS: Acute coronary syndrome; PCI: Percutaneous coronary

Disclaimer: The scientific content of this publication has been developed by Scientimed Solutions Pvt. Ltd. through an educational grant from Pfizer Ltd. This publication is distributed free of cost as a service to the medical profession for educational purpose only. The expert comments expressed in this document are solely the views of the experts/clinicians. Pfizer Ltd. does not agree nor disagree with the views expressed in this document. Although greatest possible care has been taken in compiling and checking the content of this literature to be accurate and complete, the author, the developer or the sponsor shall not be responsible or in anyway liable for any injury and/or damage to any persons in view of any errors, omissions or inaccuracies in this publication, whether arising from negligence or otherwise. We request you to please refer to the full prescribing information for detailed information.

PP-ELI-IND-2533, 04/07/2024

Full prescribing information available on request
Pfizer Limited: The Capital – A Wing, 1802, 18th Floor, Plot No. C-70, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051, India.
For the use only of Registered Medical Practitioners, or a hospital or a laboratory